Monday, April 8, 2024

7:00 AM – 8:00 AM  Continental Breakfast

8:00 AM – 10:00 AM  Morning Plenary: ITC Update and Hot Topic – Molecular Basis for Drug Transport

8:00 AM – 8:05 AM  Introduction and Welcome
Bridget Morse, Ph.D., Eli Lilly

8:05 AM – 9:00 AM  Membrane Transporters in Drug Development and as Key Determinants of Precision Medicine: An Update from the International Transporter Consortium
Alex Galetin, University of Manchester

9:00 AM – 9:30 AM  Molecular Basis of Polyspecific Drug Recognition by OCT1 and OCT2
Seok Yong Lee, Duke University

9:30 AM – 10:00 AM  Molecular Basis for Selective Uptake and Elimination of Organic Anions in the Kidney by OAT1
Representative from University of Oxford

10:00 AM – 10:30 AM  Coffee Break

10:30 AM – 12:00 PM  Session Two: Transporters Models and Methods
Wei Yue

10:30 AM – 11:00 AM  In Vitro Hepatocyte-Culture System for Biliary Excretion Analysis by Permeation Assay
Ikumi Tamai, Kanazawa University

11:00 AM – 11:30 AM  Demystifying Xenobiotic Transport Mechanisms at the Blood-CSF Barrier Using Live Tissue Imaging
Joanne Wang, University of Washington

11:30 AM – 12:00 PM  Effect of Sex and Cross-Sex Hormone Treatment on Renal Monocarboxylate-Transporter Expression in Rats
Melanie Felmee, University of the Pacific
12:00 PM – 12:30 PM  Partner Presentation

12:30 PM – 1:30 PM  Lunch and Exhibits

1:30 PM – 3:00 PM  Session Three: Emerging Transporters & Mechanisms
Paresh Chothe

1:30 PM – 2:00 PM  Nucleoside transporters
Rajgopal Govindarajan, The Ohio State University

2:00 PM – 2:30 PM  Organic Cation Transporter 2 Contributes to SSRI Antidepressant Efficacy by Controlling Tryptophan Availability in the Brain
Sophie Gautron, Sorbonne University

2:30 PM – 3:00 PM  Consequences of Altered Kinase Activity and Solute Carrier Function
Jason Sprowl, University of Buffalo

3:00 PM – 3:30 PM  Coffee Break

3:30 PM – 5:00 PM  Session Four: Rapid Fires and Partner Presentation

3:30 PM – 4:00 PM  Partner Presentation

4:00 PM – 5:00 PM  Rapid Fires

5:00 PM – 7:00 PM  Evening Reception and Exhibits

Tuesday, April 9, 2024

7:00 AM – 8:00 AM  Continental Breakfast

8:00 AM – 10:00 AM  Session Five: Rapid Fires and Partner Presentations

8:00 AM – 8:30 AM  Partner Presentation

8:30 AM – 9:30 AM  Rapid Fires

9:30 AM – 10:00 AM  Partner Presentation

10:00 AM – 10:30 AM  Coffee Break

10:30 AM – 12:00 PM  Session Six: Transporters in Clinical Pharmacology
Xinning Yang

10:30 AM – 11:00 AM  Ticagrelor Increases Exposure to the Breast Cancer Resistance Protein Substrate Rosuvastatin
Mikko Niemi, University of Helsinki
11:00 AM – 12:00 PM  Case Studies

12:00 PM – 1:00 PM  Lunch and Exhibits

1:00 PM – 5:00 PM  Session Seven: Prediction of Transporter-Mediated Clearance, DDIs and Disease Effects
Matthew Harwood
Bridget Morse, Ph.D., Eli Lilly

1:00 PM – 1:30 PM  Transporter-Mediated Clearance and Drug-Drug Interactions – Identifying Mechanisms and Predicting Effect Size
Manthena Varma, Pfizer, Inc.

1:30 PM – 2:00 PM  Plasma Protein-Mediated Uptake and Contradictions to the Free Drug Hypothesis: A Critical Review
John Cory Kalvass, AbbVie

2:00 PM – 2:30 PM  Toward Improved Predictions of Pharmacokinetics of Transported Drugs in Hepatic Impairment: Insights from the Extended Clearance Model
Flavia Storelli, University of Washington

2:30 PM – 3:00 PM  Coffee Break

3:00 PM – 3:30 PM  Clinical Implications of Altered Drug Transporter Abundance/Function and PBPK Modeling in Specific Populations: An ITC Perspective
Xiaoyan Chu, Merck & Co., Inc.

3:30 PM – 4:00 PM  Renal Transporter Alterations in Patients with Chronic Liver Diseases: Nonalcoholic Steatohepatitis, Alcohol-Associated, Viral Hepatitis, and Alcohol-Viral Combination
Nathan Cherrington, University of Arizona

4:00 PM – 4:30 PM  Predicting Statin-Roxadustat Drug-Drug Interaction in Patients with Severe Chronic Kidney Disease to Support Prescribing Information Using Physiologically Based Pharmacokinetic Modelling
Jin Dong, AstraZeneca

4:30 PM – 5:00 PM  Prediction of Transporter-Mediated Clearance, DDIs and Disease Effects Panel Discussion

5:00 PM – 7:00 PM  Evening Reception and Exhibits
**Wednesday, April 10, 2024**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00 AM – 8:00 AM</td>
<td>Continental Breakfast</td>
<td></td>
</tr>
<tr>
<td>8:00 AM – 10:00 AM</td>
<td><strong>Session Eight: Regulatory Considerations</strong></td>
<td>Xiaoyan Chu</td>
</tr>
<tr>
<td>8:00 AM – 8:30 AM</td>
<td>Harmonization on DDI Guidances for Transporters-Mediated DDIs: Current Status and Future</td>
<td>Xinning Yang, Ph.D., FDA</td>
</tr>
<tr>
<td>8:30 AM – 9:00 AM</td>
<td>Regulatory Considerations for Transporter Mediated Drug-Drug Interactions (EMA Perspective)</td>
<td>Carolien Versantvoort, European Medicines Agency</td>
</tr>
<tr>
<td>9:00 AM – 9:30 AM</td>
<td>Trends in FDA Transporter-Based Post-Marketing Requirements and Commitments Over the Last Decade</td>
<td>Islam Younis, Merck &amp; Co., Inc.</td>
</tr>
<tr>
<td>9:30 AM – 10:15 AM</td>
<td>Panel Discussion</td>
<td></td>
</tr>
<tr>
<td><strong>10:15 AM – 10:45 AM</strong></td>
<td><strong>Coffee Break</strong></td>
<td></td>
</tr>
<tr>
<td><strong>10:45 AM – 12:00 PM</strong></td>
<td><strong>Session Nine: Closing Keynote</strong></td>
<td>Wei Yue</td>
</tr>
<tr>
<td>10:45 AM – 11:45 AM</td>
<td>The Mitochondrial Transporter ABCB10 Regulates Redox and Cell-to-Cell Communication in Metabolic Diseases</td>
<td>Marc Liesa, Spanish National Research Council</td>
</tr>
<tr>
<td>11:45 AM – 12:00 PM</td>
<td>Closing Remarks</td>
<td>Bridget Morse, Ph.D., Eli Lilly</td>
</tr>
</tbody>
</table>